Researchers identify immune-suppressing target in glioblastoma
Researchers at The University of Texas MD Anderson Cancer Center have identified a tenacious subset of immune macrophages that thwart treatment of glioblastoma with anti-PD-1 checkpoint blockade, elevating a new potential target for treating the almost uniformly lethal brain tumor.
Their findings, reported in Nature Medicine, identify macrophages that express high levels of CD73, a surface enzyme that’s a vital piece of an immunosuppressive...
Minimum age to purchase tobacco products in US raised to 21
HOUSTON ― The University of Texas MD Anderson Cancer Center applauds the bipartisan legislation approved today raising the legal age...
Breast biopsies after neoadjuvant chemotherapy accurately predict presence of residual breast cancer
Abstract: GS5-04
Researchers from The University of Texas MD Anderson Cancer Center have identified a standardized protocol that uses...
Residual cancer burden after neoadjuvant therapy can accurately predict breast cancer survival
Abstract: GS5-01
Researchers from The University of Texas MD Anderson Cancer Center today reported results from a pooled analysis of more than 5,100 breast cancer patients that found residual cancer burden (RCB) continuous index and classification were independently and strongly prognostic for all breast cancer phenotypes.
The study’s results were presented by W. Fraser Symmans, M.D., professor of Pathology, during the 2019...
Statement regarding the confirmation of Stephen Hahn, M.D., as United States Commissioner of Food and Drugs
The faculty and staff at The University of Texas MD Anderson Cancer Center congratulate Stephen Hahn, M.D., on his confirmation as United...
Adding tucatinib to drug combination extends survival for advanced HER2+ breast cancer patients
Abstract: GS1-01
Researchers from The University of Texas MD Anderson Cancer Center today reported study results showing the addition...
Combination therapy results in 98% response rate for some newly diagnosed leukemia patients
A study led by The University of Texas MD Anderson Cancer Center showed that treatment combining lower doses of chemotherapy with the monoclonal...
CAR T-cell therapy effective for relapsed mantle cell lymphoma patients
A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell lymphoma...
Combination therapy more effective than chemotherapy alone for many newly diagnosed leukemia patients
A multi-institutional, Phase II study led by The University of Texas MD Anderson Cancer Center showed that pairing standard chemotherapy azacitidine...
MD Anderson-convened consortium provides first universal recommendations for pediatric patients with sinusoidal obstructive syndrome
The University of Texas MD Anderson Cancer Center convened an international panel of multidisciplinary experts earlier this year to evaluate...
Acupuncture reduces radiation-induced dry mouth for cancer patients
After receiving acupuncture treatment three days a week during the course of radiation treatment, head and neck cancer patients experienced...
MD Anderson clinical trial expert Lee earns election as AAAS Fellow
J. Jack Lee, Ph.D., associate vice president of Quantitative Sciences and Biostatistics at The University of Texas MD Anderson Cancer Center...
Researchers find protein promotes cancer, suppresses anti-tumor immunity
Researchers at The University of Texas MD Anderson Cancer Center have found that a protein involved in immune response to microbes also can...
A Conversation With a Living Legend to honor Houston Astros’ Jim Crane
The University of Texas MD Anderson Cancer Center will honor business entrepreneur and philanthropist Jim Crane, owner and chairman of the...